Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack Praluent is the only EU-approved PCSK9 inhibitor with ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
The FINANCIAL — Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent ...
ORLANDO, Fla.—As the American College of Cardiology's annual meeting kicked off in Orlando Saturday, all eyes turned to Sanofi and Regeneron, who reported that their PCSK9 drug Praluent reduced the ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...
ORLANDO, Fla.-- A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the ...
The sBLA is supported by data from the Phase 3 ODYSSEY OUTCOMES trial which included 18,924 patients who had experienced an acute coronary syndrome (ACS) in the previous 12 months. The Food and Drug ...
Sanofi and Regeneron have made their bid for a Praluent reprieve. In the wake of a district judge’s patent ruling that could push the partners’ new cholesterol drug off the market, the two companies ...
Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks TARRYTOWN, N.Y. and PARIS, Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback